Abstract

The WT1 gene, characterized by an extremely complex structure, is located on chromosome 11. It is involved in cell growth and differentiation, and has a strong impact on consecutive stages of the functioning of the body. The WT1 gene may undergo many different mutations, as well as may be overexpressed without a mutation. The molecular basis of diseases such as Wilms tumor, WAGR, Denys-Drash or Frasier syndromes are congenital WT1 mutations, while somatic mutations of this gene occur in acute and chronic myeloid leukemia, myelodysplastic syndrome and also in some other blood neoplasms, as acute lymphoblood leukemia. Increased expression of this gene without its mutation is observed in leukemias and solid tumors. The WT1 may function both as a tumor suppressor gene and as an oncogene. The diversity of WT1 changes causes many controversies, therefore investigations are still carried out to determine the function of this gene, its interaction with other molecules and its prognostic significance in various diseases.

References

• 1. Baba M., Hata T., Tsushima H., Mori S., Sasaki D., Turuta K., Hasegawa H., Ando K., Sawayama Y., Imanishi D., Taguchi J., Yanagihara K., Tomonaga M., Kamihira S., Miyazaki Y.: The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons. Intern. Med., 2015; 54: 445-451
  Google Scholar
• 2. Barbaux S., Niaudet P., Gubler M.C., Grünfeld J.P., Jaubert F., Kuttenn F., Fékété C.N., Souleyreau-Therville N., Thibaud E., Fellous M., McElreavey K.: Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat. Genet., 1997; 17: 467-470
  Google Scholar
• 3. Barragán E., Cervera J., Bolufer P., Ballester S., Martín G., Fernández P., Collado R., Sayas M.J., Sanz M.A.: Prognostic implications of Wilms’ tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica, 2004; 89: 926-933
  Google Scholar
• 4. Bergmann L., Miething C., Maurer U., Brieger J., Karakas T., Weidmann E., Hoelzer D.: High levels of Wilms’ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood, 1997; 90: 1217-1225
  Google Scholar
• 5. Busse A., Gökbuget N., Siehl J.M., Hoelzer D., Schwartz S., Rietz A., Thiel E., Keilholz U.: Wilms’ tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann. Hematol., 2009; 88: 1199-1205
  Google Scholar
• 6. Clericuzio C.L.: WAGR syndrome. W: Management of Genetic Syndromes, red.: Cassidy S.B., Allanson J.E., John Wiley & Sons, New York, 2005; 645-653
  Google Scholar
• 7. Foran J.M.: New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology, 2010; 2010: 47-55
  Google Scholar
• 8. Gaidzik V.I., Schlenk R.F., Moschny S., Becker A., Bullinger L., Corbacioglu A., Krauter J., Schlegelberger B., Ganser A., Döhner H., Döhner K.: Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia a study of the German-Austrian AML Study Group. Blood, 2009; 113: 4505-4511
  Google Scholar
• 9. Galimberti S., Ghio F., Guerrini F., Ciabatti E., Grassi S., Ferreri M.I., Petrini M.: WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes. Br. J. Haematol., 2010; 149: 451-464
  Google Scholar
• 10. Guo J.K., Menke A.L., Gubler M.C., Clarke A.R., Harrison D., Hammes A., Hastie N.D., Schedl A.: WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum. Mol. Genet., 2002; 11: 651-659
  Google Scholar
• 11. Gwin K., Cajaiba M.M., Caminoa-Lizarralde A., Picazo M.L., Nistal M., Reyes-Múgica M.: Expanding the clinical spectrum of Frasier syndrome. Pediatr. Dev. Pathol., 2008; 11: 122-127
  Google Scholar
• 12. Heesch S., Goekbuget N., Stroux A., Tanchez J.O., Schlee C., Burmeister T., Schwartz S., Blau O., Keilholz U., Busse A., Hoelzer D., Thiel E., Hofmann W.K., Baldus C.D.: Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica, 2010; 95: 942-949
  Google Scholar
• 13. Ho P.A., Zeng R., Alonzo T.A., Gerbing R.B., Miller K.L., Pollard J.A., Stirewalt D.L., Heerema N.A., Raimondi S.C., Hirsch B., Franklin J.L., Lange B., Meshinchi S.: Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children’s Oncology Group. Blood, 2010; 116: 702-710
  Google Scholar
• 14. Hollink I.H., van den Heuvel-Eibrink M.M., Zimmermann M., Balgobind B.V., Arentsen-Peters S.T., Alders M., Willasch A., Kaspers G.J., Trka J., Baruchel A., de Graaf S.S., Creutzig U., Pieters R., Reinhardt D., Zwaan C.M.: Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood, 2009; 113: 5951-5960
  Google Scholar
• 15. Hou H.A., Chou W.C., Tien H.F.: Genetic alterations and their clinical implications in acute myeloid leukemia. W: Myeloid Leukemia – Basic Mechanisms of Leukemogenesis, red.: Koschmieder S., Krug U., InTech, 2011; 163-184
  Google Scholar
• 16. Huff V.: Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat. Rev. Cancer, 2011; 11: 111-121
  Google Scholar
• 17. Ibrahim A., Badrawy H., Sayed H.: Prognostic implications of expression of the Wilms tumor 1 (WT1) gene in acute leukemia (Experience from South Egypt). BJMMR, 2015; 7: 61-71
  Google Scholar
• 18. Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., Kita K., Hiraoka A., Masaoka T., Nasu K., Kyo T., Dohy H., Nakauchi H., Ishidate T., Akiyama T., Kishimoto T.: WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood, 1994; 84: 3071-3079
  Google Scholar
• 19. Kerst G., Bergold N., Gieseke F., Coustan-Smith E., Lang P., Kalinova M., Handgretinger R., Trka J., Müller I.: WT1 protein expression in childhood acute leukemia. Am. J. Hematol., 2008; 83: 382-386
  Google Scholar
• 20. Kęsy J., Januszkiewicz-Lewandowska D.: Genes and childhood leukemia. Postępy Hig. Med. Dośw., 2015; 69: 302-308
  Google Scholar
• 21. Klamt B., Koziell A., Poulat F., Wieacker P., Scambler P., Berta P., Gessler M.: Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1+/-KTS splice isoforms. Hum. Mol. Genet., 1998; 7: 709-714
  Google Scholar
• 22. Kubiak A., Niemir Z.I.: Znaczenie podocytów w prawidłowym funkcjonowaniu kłębuszka nerkowego oraz w patogenezie kłębuszkowych zapaleń nerek. Część I. Charakterystyka fenotypowa i czynność podocytów w okresie ich różnicowania się i dojrzałości. Postępy Hig. Med. Dośw., 2006; 60: 248-258
  Google Scholar
• 23. Lapillonne H., Renneville A., Auvrignon A., Flamant C., Blaise A., Perot C., Lai J.L., Ballerini P., Mazingue F., Fasola S., Dehée A., Bellman F., Adam M., Labopin M., Douay L., Leverger G., Preudhomme C., Landman-Parker J.: High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J. Clin. Oncol., 2006; 24: 1507-1515
  Google Scholar
• 24. Lee S.B., Haber D.A.: Wilms tumor and the WT1 gene. Exp. Cell Res., 2001; 264: 74-99
  Google Scholar
• 25. Lopotová T., Polák J., Schwarz J., Klamová H., Moravcová J.: Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four realtime RT PCRs. Blood Cells Mol. Dis., 2012; 49: 41-47
  Google Scholar
• 26. Lyu X., Xin Y., Mi R., Ding J., Wang X., Hu J., Fan R., Wei X., Song Y., Zhao R.Y.: Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia. PLoS One, 2014; 9: e92470
  Google Scholar
• 27. Morrison A.A., Viney R.L., Ladomery M.R.: The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim. Biophys. Acta, 2008; 1785: 55-62
  Google Scholar
• 28. Mossallam G.I., Abdel Hamid T.M., Mahmoud H.K.: Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients. Hematology, 2013; 18: 69-73
  Google Scholar
• 29. Mrowka C., Schedl A.: Wilms’ tumor suppressor gene WT1: from structure to renal pathophysiologic features. J. Am. Soc. Nephrol., 2000; 11, (Suppl. 16): S106-S115
  Google Scholar
• 30. Noronha S.A., Farrar J.E., Alonzo T.A., Gerbing R.B., Lacayo N.J., Dahl G.V., Ravindranath Y., Arceci R.J., Loeb D.M.: WT1 expression at diagnosis does not predict survival in pediatric AML: A report from the Children’s Oncology Group. Pediatr. Blood Cancer, 2009; 53: 1136-1139
  Google Scholar
• 31. Østergaard M., Olesen L.H., Hasle H., Kjeldsen E., Hokland P.: WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single-centre study. Br. J. Haematol., 2004; 125: 590-600
  Google Scholar
• 32. Owen C., Fitzgibbon J., Paschka P.: The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol. Oncol., 2010; 28: 13-19
  Google Scholar
• 33. Paschka P., Marcucci G., Ruppert A.S., Whitman S.P., Mrózek K., Maharry K., Langer C., Baldus C.D., Zhao W., Powell B.L., Baer M.R., Carroll A.J., Caligiuri M.A., Kolitz J.E., Larson R.A., Bloomfield C.D.: Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol., 2008; 26: 4595-4602
  Google Scholar
• 34. Pellagatti A., Benner A., Mills K.I., Cazzola M., Giagounidis A., Perry J., Malcovati L., Della Porta M.G., Jädersten M., Verma A., McDonald E.J., Killick S., Hellström-Lindberg E., Bullinger L., Wainscoat J.S., Boultwood J.: Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. J. Clin. Oncol., 2013; 31: 3557-3564
  Google Scholar
• 35. Pelletier J., Bruening W., Kashtan C.E., Mauer S.M., Manivel J.C., Striegel J.E., Houghton D.C., Junien C., Habib R., Fouser L., Fine R.N., Silverman B.L., Haber D.A., Housman D.: Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell, 1991; 67: 437-447
  Google Scholar
• 36. Pelletier J., Bruening W., Li F.P., Haber D.A., Glaser T., Housman D.E.: WT1 mutations contribute to abnormal genital system development and hereditary Wilms’ tumour. Nature, 1991; 353: 431-434
  Google Scholar
• 37. Qi X.W., Zhang F., Wu H., Liu J.L., Zong B.G., Xu C., Jiang J.: Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci. Rep., 2015; 5: 8924
  Google Scholar
• 38. Regev M., Kirk R., Mashevich M., Bistritzer Z., Reish O.: Vertical transmission of a mutation in exon 1 of the WT1 gene: lessons for genetic counseling. Am. J. Med. Genet. A, 2008; 146A: 2332-2336
  Google Scholar
• 39. Renneville A., Boissel N., Zurawski V., Llopis L., Biggio V., Nibourel O., Philippe N., Thomas X., Dombret H., Preudhomme C.: Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer, 2009; 115: 3719-3727
  Google Scholar
• 40. Scharnhorst V., van der Eb A.J., Jochemsen A.G.: WT1 proteins: functions in growth and differentiation. Gene, 2001; 273: 141-161
  Google Scholar
• 41. Shen Y., Zhu Y.M., Fan X., Shi J.Y., Wang Q.R., Yan X.J., Gu Z.H., Wang Y.Y., Chen B., Jiang C.L., Yan H., Chen F.F., Chen H.M., Chen Z., Jin J., Chen S.J.: Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood, 2011; 118: 5593-5603
  Google Scholar
• 42. Spassov B.V., Stoimenov A.S., Balatzenko G.N., Genova M.L., Peichev D.B., Konstantinov S.M.: Wilms’ tumor protein and FLT3-internal tandem duplication expression in patients with de novo acute myeloid leukemia. Hematology, 2011; 16: 37-42
  Google Scholar
• 43. Sugiyama H.: Wilms’ tumor gene WT1: its oncogenic function and clinical application. Int. J. Hematol., 2001; 73: 177-187
  Google Scholar
• 44. Sugiyama H.: WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn. J. Clin. Oncol., 2010; 40: 377-387
  Google Scholar
• 45. Szántó A., Pap Z., Dénes L., Benedek Lázár E., Horváth A., Tunyogi A.B., Baróti B.Á., Pávai Z.: Real-time quantitative PCR detection of WT1 and M-BCR-ABL expressions in chronic myeloid leukemia. Rom. J. Morphol. Embryol., 2015; 56 (Suppl. 1): 703-707
  Google Scholar
• 46. Tosello V., Mansour M.R., Barnes K., Paganin M., Sulis M.L., Jenkinson S., Allen C.G., Gale R.E., Linch D.C., Palomero T., Real P., Murty V., Yao X., Richards S.M., Goldstone A. i wsp.: WT1 mutations in T-ALL. Blood, 2009; 114: 1038-1045
  Google Scholar
• 47. Trka J., Kalinová M., Hrusák O., Zuna J., Krejci O., Madzo J., Sedlácek P., Vávra V., Michalová K., Jarosová M., Starý J.: Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia, 2002; 16: 1381-1389
  Google Scholar
• 48. Ueda Y., Mizutani C., Nannya Y., Kurokawa M., Kobayashi S., Takeuchi J., Tamura H., Ogata K., Dan K., Shibayama H., Kanakura Y., Niimi K., Sasaki K., Watanabe M., Emi N. i wsp.: Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Leuk. Lymphoma, 2013; 54: 1450-1458
  Google Scholar
• 49. Virappane P., Gale R., Hills R., Kakkas I., Summers K., Stevens J., Allen C., Green C., Quentmeier H., Drexler H., Burnett A., Linch D., Bonnet D., Lister T.A., Fitzgibbon J.: Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J. Clin. Oncol., 2008; 26: 5429-5435
  Google Scholar
• 50. Wasilewska A., Zoch-Zwierz W., Tenderenda E., Rybi-Szumińska A., Kołodziejczyk Z.: Mutacja genu WT1 jako przyczyna postępują- cej nefropatii w zespole Frasiera – opis przypadku. Pol. Merk. Lek., 2009; 26: 642-644
  Google Scholar
• 51. WT1 gene. https://ghr.nlm.nih.gov/gene/WT1#location (21.03.2016)
  Google Scholar
• 52. Yanada M., Terakura S., Yokozawa T., Yamamoto K., Kiyoi H., Emi N., Kitamura K., Kohno A., Tanaka M., Tobita T., Takeo T., Sao H., Kataoka T., Kobayashi M., Takeshita A., Morishita Y., Naoe T., Sugiura I.: Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk. Lymphoma, 2004; 45: 1803-1808
  Google Scholar
• 53. Yang L., Han Y., Saurez Saiz F., Minden M.D.: A tumor suppressor and oncogene: the WT1 story. Leukemia, 2007; 21: 868-876
  Google Scholar
• 54. Yohe S.: Molecular genetic markers in acute myeloid leukemia. J. Clin. Med., 2015; 4: 460-478
  Google Scholar

Full text